2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161094
    Metallo-β-lactamase-IN-12 3028594-43-3 98%
    Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and serine β-lactamases (SβLs (OXA-48, KPC-2)), with IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity.
    Metallo-β-lactamase-IN-12
  • HY-161097
    Antibacterial agent 171 98%
    Antibacterial agent 171 (Compound 28) is an antibacterial agent. Antibacterial agent 171 inhibits gram-negative bacteria.
    Antibacterial agent 171
  • HY-161114
    MDOLL-0229 3036752-42-5 98%
    MDOLL-0229 (compound 27) is an antiviral agent that targets SARS-CoV-2 Mac1 and repress coronavirus replication. MDOLL-0229 inhibits SARS-CoV-2 Mac1 with an IC50 of 2.1 µM.
    MDOLL-0229
  • HY-161124
    SrtA-IN-2 98%
    SrtA-IN-2 (compound Y40), a ML346 (HY-18669) analog, is a Sortase A (SrtA) inhibitor. SrtA-IN-2 shows inhibitory activity on Staphylococcus aureus SrtA and shows inhibitory effects on biofilm formation. SrtA-IN-2 is an antivirulence agent against S. aureus infections.
    SrtA-IN-2
  • HY-161172
    Antibacterial agent 178 98%
    Antibacterial agent 178 (compound A10) is a potent antibacterial agent. Antibacterial agent 178 shows antibacterial activities for Xanthomonas oryzae pv. oryzae and Xanthomonas oryzae pv. oryzicola with EC50s of 5.32 mg/L and 7.58 mg/L, respectively. Antibacterial agent 178 targets the translational regulator (CsrA) and the virulence regulator (Xoc3530).
    Antibacterial agent 178
  • HY-161239
    (S)-IB-96212 98%
    (S)-IB-96212 (compound 4), an oligomycin derivative, inhibits the MurD2 reaction, but not the MurL reaction. (S)-IB-96212 is a specific inhibitor of the alternative pathway of peptidoglycan biosynthesis. (S)-IB-96212 weakly inhibits the MurD reaction.
    (S)-IB-96212
  • HY-161292
    DHFR-IN-16 98%
    DHFR-IN-16 (compound 8d) is an inhibitor of dihydrofolate reductase (DHFR) (IC50=0.199 μM) and can be used in anti-infectious research.
    DHFR-IN-16
  • HY-161330
    Anti-MRSA agent 10 98%
    Anti-MRSA agent 10 (Compound 2d) is a Cephalosporin (HY-144229) derivative and exhibits antibacterial activity. Anti-MRSA agent 10 is slightly drug resistane and exhibits low cytotoxicity in cells HUVEC and HBZY-1.
    Anti-MRSA agent 10
  • HY-161357
    KR-27370 3097359-18-4 98%
    KR-27370 (compound 7f) is an antiviral agent and selective PI4KIIIβ/PI4KIIIα inhibitor (IC50: 3.1 nM/15.8 nM), against hRV, Ke Saatchivirus and other enteroviruses have inhibitory activity.
    KR-27370
  • HY-161380
    Antifungal agent 96 98%
    Antifungal agent 96 (Compound WZ-2) is an antifungal agent with good blood-brain barrier permeability and brain penetration. Antifungal agent 96 inhibits the growth of C. neoformans H99 and C. albicans 0304103 with MIC values of 0.016 and 32 μg/mL, respectively.
    Antifungal agent 96
  • HY-161457
    (Gly0.8Nap0.2)20 98%
    (Gly0.8Nap0.2)20 is a compound that dual targets fungal membranes and DNA. (Gly0.8Nap0.2)20 has antibacterial activity.
    (Gly0.8Nap0.2)20
  • HY-16158R
    Cyclacillin (Standard) 3485-14-1
    DL-Glutamic acid (Standard) is the analytical standard of DL-Glutamic acid. This product is intended for research and analytical applications. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability.
    Cyclacillin (Standard)
  • HY-161689
    Antibacterial agent 220 98%
    Antibacterial agent 220 is a potent antibacterial agent that can directly destroy bacterial cell membranes. Antibacterial agent 220 effectively combats Gram-positive and and Gram-negative pathogens, including drug-resistant strains.
    Antibacterial agent 220
  • HY-161728
    Antibacterial agent 223 833432-18-1 98%
    Antibacterial agent 223 (compound D8-03) is an inhibitor of Francisella tularensis. Antibacterial agent 223 can inhibit intracellular growth of Francisella tularensis in mice.
    Antibacterial agent 223
  • HY-161729
    PLpro-IN-3 3047093-72-8 98%
    PLpro-IN-3 (compound 26R) is a potent Papain-like protease (PLpro) inhibitor with a IC50 of 1.0μM. PLpro-IN-3 exhibits antiviral activity against SARS-CoV-2 with a EC50 of 4.3 μM.
    PLpro-IN-3
  • HY-161756
    DNA Gyrase-IN-10 98%
    DNA Gyrase-IN-10 is a potent DNA gyrase inhibitor with potent antibacterial effects. DNA Gyrase-IN-10 has inhibitory effects on both Gram-positive and Gram-negative bacteria.
    DNA Gyrase-IN-10
  • HY-161758
    F0045(S) 2716077-17-5 98%
    F0045(S) is a potent influenza hemagglutinin inhibitor with a KD value of 6.1 µM. F0045(S) protects human cells from influenza infection.
    F0045(S)
  • HY-161761
    Urease-IN-15 98%
    Urease-IN-15 (compound 5g) is an uncompetitive inhibitor of urease in manner with the IC50 of 3.80 µM.
    Urease-IN-15
  • HY-161771
    JNJ-7184 2347368-51-6 98%
    JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, with the pEC50 and pCC50 of 7.86 and 4.29 in Hela cells, respectively. JNJ-7184 prevents RSV replication and transcription by inhibiting initiation or early elongation.
    JNJ-7184
  • HY-161777
    SARS-CoV-2 Mpro-IN-23 98%
    SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM.
    SARS-CoV-2 Mpro-IN-23
Cat. No. Product Name / Synonyms Application Reactivity